A Monte Carlo t Test to Evaluate Mesothelioma and Radiation in the US Transuranium and Uranium Registries.

A Monte Carlo t Test to Evaluate Mesothelioma and Radiation in the US Transuranium and Uranium Registries. Health Phys. 2019 Aug;117(2):187-192 Authors: Zhou JY, McComish SL, Tolmachev SY Abstract A cluster of nine mesothelioma cases was observed among 341 registrants' deaths in the US Transuranium and Uranium Registries. Descriptive analysis showed that mesothelioma cases had the highest average cumulative external radiation dose compared with lung cancer, other cancer, and noncancer deaths. Further analysis indicated that the mesothelioma cluster was very different demographically from lung cancer, other cancer, and noncancer deaths. Therefore, an internally matched case-control approach was applied to evaluate the differences in an average cumulative external radiation dose between mesothelioma deaths and other causes of death. A Monte Carlo t test was used to examine the statistical significance of the differences. The results showed that there were no significant statistical differences in an average cumulative external radiation dose between mesothelioma and lung cancer, other cancers, or noncancers for the internally matched cases and controls. PMID: 31225828 [PubMed - in process]
Source: Health Physics - Category: Physics Authors: Tags: Health Phys Source Type: research

Related Links:

AbstractBackground.Multimodality therapy with preoperative radiation (RT) followed by extrapleural pneumonectomy (EP) for patients with operable malignant pleural mesothelioma (MPM) has demonstrated encouraging results. At relapse, there are few data on the tolerance and efficacy of systemic therapies after prior multimodality therapy.Materials and Methods.We conducted a retrospective analysis of patients with relapsed MPM after RT and EPP ± adjuvant chemotherapy to determine overall survival (OS; date of relapse to death) and the proportion of patients that received systemic therapy and associated response rate (RR...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer Source Type: research
Malignant Pleural Mesothelioma (MPM) is an aggressive tumor that arises from the mesothelial cells of the pleura [1]. It is well established that MPM is almost always caused by professional or non professional exposure to asbestos fibers, while the pathogenetic role of cofactors, such as SV40 viral infection, still remains controversial [2,3]. The average latency period between asbestos exposure and tumor presentation is 30-45 years, depending on duration or intensity of exposure and patient gender [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Abstract Pemetrexed (PMX) is a multi-targeted antifolate drug used for the treatment of malignant pleural mesothelioma (MPM) and non-small cell lung cancer. Hyaluronan (HA) in blood is well known as a disease marker of MPM. We synthesized PMX-conjugated hyaluronan (HA-ADH-PMX) for the first time to develop a novel anticancer chemotherapeutic agent. HAs with different molecular weights (76 and 130 kDa) were first derivatized with adipic dihydrazide (ADH) and then conjugated to PMX. The obtained HA-ADH-PMX retained inhibitory activity against folate metabolism enzymes; thymidylate synthase was inhibited to the sam...
Source: European Journal of Pharmaceutical Sciences - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharm Sci Source Type: research
Specially trained beagles could one day detect mesothelioma by scent, according to the lead researcher of a recent study detailing the dog breed’s stunning accuracy with lung cancer. Dr. Thomas Quinn, clinical professor at the Lake Erie College of Osteopathic Medicine, believes the dogs could be equally effective with pleural mesothelioma, a rare cancer caused by asbestos exposure. “Absolutely, this could work with mesothelioma. There is no reason why it wouldn’t,” Quinn told The Mesothelioma Center at Asbestos.com. “That is another cancer with strong potential for this to work well.” Th...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A coalition of attorneys general from 10 states and the District of Columbia has filed a federal lawsuit against the Environmental Protection Agency seeking increased scrutiny on asbestos products. The lawsuit is challenging the EPA’s reluctance to initiate tighter controls or an outright ban of asbestos within the Toxic Substances Control Act, which was revised in 2016. At issue is the EPA’s denial of a petition filed by 15 attorneys general in January that would have required more data collection and tracking of chemicals, including asbestos, coming into the U.S. The lawsuit says the data collection is necess...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A cluster of nine mesothelioma cases was observed among 341 registrants’ deaths in the US Transuranium and Uranium Registries. Descriptive analysis showed that mesothelioma cases had the highest average cumulative external radiation dose compared with lung cancer, other cancer, and noncancer deaths. Further analysis indicated that the mesothelioma cluster was very different demographically from lung cancer, other cancer, and noncancer deaths. Therefore, an internally matched case-control approach was applied to evaluate the differences in an average cumulative external radiation dose between mesothelioma deaths and o...
Source: Health Physics - Category: Radiology Tags: PAPERS Source Type: research
A research team from the Duke University Medical Center and the Massachusetts Institute of Technology has uncovered a new compound with potential to make chemotherapy more effective in treating various cancers. The small-molecule inhibitor drug — JH-RE-06 — showed an ability to better-sensitize tumors to Cisplatin, the popular chemotherapy drug most often used for mesothelioma cancer patients. When combined with Cisplatin, the drug also showed an ability to prevent those tumor cells from becoming treatment resistant, a common problem with this rare cancer caused by asbestos exposure. The research was done on l...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Interventional oncology and management of thoracic malignancies with ablative techniques are becoming ever more recognized therapeutic options. With increased understanding, development, and utility of the ablative techniques, the indications are expanding and efficacy improving. Lung cancer was among the first indications for lung ablation and remains most challenging with multiple therapeutic options. For inoperable patients, the current literature demonstrates equivalent survivals between ablation, sublobar resection, and stereotactic body radiation. Oligometastatic disease remains the most common indication for lung ab...
Source: Journal of Thoracic Imaging - Category: Radiology Tags: Symposium: Imaging of Innovative and Contemporary Thoracic Interventions: State-of-the-Art Source Type: research
The influential American Chemistry Council in Washington, D.C., would likely drop its opposition to an across-the-board ban on asbestos provided an exemption remains for the chlor-alkali industry. Mike Walls, ACC vice president for regulatory affairs, clarified his position last month during a congressional Environment and Climate Change subcommittee hearing to discuss the latest legislative effort to ban all asbestos. “We certainly are not opposing a ban for all other uses of asbestos. I just want to make that clear,” Walls said. “The ACC’s opposition [on legislation] is focused on the impact on t...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Hidetaka Uramoto It is not clear whether magnetic resonance imaging (MRI) is useful for the assessment of pleural diseases. The aim of this study is to determine whether diffusion-weighted magnetic resonance imaging (DWI) can differentiate malignant pleural mesothelioma (MPM) from pleural dissemination of lung cancer, empyema or pleural effusion. The DWI was calibrated with the b value of 0 and 800 s/mm2. There were 11 MPMs (8 epithelioid and 3 biphasic), 10 pleural disseminations of lung cancer, 10 empyemas, and 12 pleural effusions. The apparent diffusion coefficient (ADC) of the pleural diseases was 1.22 &plu...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Lung Cancer | Mesothelioma | Physics | Statistics